ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ARS Pharmaceuticals, Inc. (SPRY) Healthcare & Pipeline Overview

ARS Pharmaceuticals, Inc. (SPRY) is a biotechnology company specializing in developing innovative treatments for severe allergic reactions, particularly through its novel intranasal epinephrine spray, ARS-1 (Neffy). Targeting a market underserved by traditional injectable epinephrine, SPRY aims to offer a more convenient and accessible solution for patients at risk.

What Is the Investment Thesis for SPRY?

ARS Pharmaceuticals presents a notable research candidate within the biotechnology sector, driven by its innovative intranasal epinephrine spray, Neffy. The company's focus on addressing the limitations of traditional epinephrine auto-injectors positions it to capture a significant share of the anaphylaxis treatment market. Key value drivers include the potential FDA approval of Neffy, which could occur in the near term, and subsequent commercialization efforts. The company's gross margin of 75.8% indicates strong potential profitability upon market entry. However, the company's negative profit margin of -203.3% reflects ongoing R&D expenses. Upcoming clinical trial results and regulatory decisions represent crucial catalysts. Potential risks include regulatory setbacks, competition from existing epinephrine products, and the need for additional funding.

Based on FMP financials and quantitative analysis

SPRY Key Highlights

Market capitalization of $547M, reflecting investor confidence in the company's potential.

• Gross margin of 75.8%, indicating strong potential profitability for Neffy.
• Beta of 0.93, suggesting the stock is slightly less volatile than the overall market.
• Focus on ARS-1 (Neffy), a novel intranasal epinephrine spray, addressing a significant unmet need in anaphylaxis treatment.
• Richard E. Lowenthal leads the company as CEO, managing a team of 155 employees.

Who Are SPRY's Competitors?

SPRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SPRY's Key Strengths?

Novel needle-free epinephrine delivery system.

• Potential for faster and more convenient administration.
• Addresses a significant unmet need in the anaphylaxis market.
• Strong intellectual property protection.

What Are SPRY's Weaknesses?

Reliance on a single product (Neffy).

• Negative profit margin due to ongoing R&D expenses.
• Requires regulatory approval for commercialization.
• Limited commercial infrastructure.

What Could Drive SPRY Stock Higher?

FDA review and potential approval of Neffy (ARS-1) in the next 6-12 months.

• Continued clinical trials to support the safety and efficacy of Neffy.
• Progress in securing commercial partnerships for market access.

What Are the Key Risks for SPRY?

Financial-distress signal — its Altman Z-Score of -2.55 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory setbacks or delays in the approval of Neffy.
• Competition from existing epinephrine auto-injectors and other emerging therapies.
• Need for additional funding to support ongoing research and development.
• Dependence on the successful commercialization of a single product.

What Are the Growth Opportunities for SPRY?

• Expansion into Pediatric Market: A significant growth opportunity lies in expanding the use of Neffy into the pediatric market. Children often experience anxiety and fear associated with needle injections, making a needle-free option like Neffy particularly appealing. Securing regulatory approval for pediatric use and developing child-friendly marketing campaigns could significantly increase market penetration. The market size for pediatric allergy treatments is substantial, with a projected value exceeding $5 billion by 2030.
• Geographic Expansion: ARS Pharmaceuticals can pursue geographic expansion by seeking regulatory approvals in Europe and other international markets. Anaphylaxis is a global health concern, and the demand for convenient epinephrine delivery methods exists worldwide. Entering new markets would diversify revenue streams and reduce reliance on the US market. The European allergy market is estimated to be worth over $8 billion annually.
• Partnerships and Licensing Agreements: Collaborating with established pharmaceutical companies through partnerships and licensing agreements can accelerate the commercialization of Neffy. Leveraging the distribution networks and marketing expertise of larger companies can facilitate market access and increase sales. Strategic alliances can also provide funding for further research and development. The timeline for securing such partnerships is typically 12-18 months.
• Development of New Formulations: ARS Pharmaceuticals can invest in developing new formulations of ARS-1 to address different patient needs and preferences. This could include variations in dosage, flavors, or delivery mechanisms. Expanding the product portfolio can enhance the company's competitive advantage and attract a wider range of customers. The market for novel drug formulations is continuously growing, driven by advancements in drug delivery technology.
• Direct-to-Consumer Marketing: Implementing a direct-to-consumer (DTC) marketing strategy can increase awareness and demand for Neffy. By educating consumers about the benefits of intranasal epinephrine and highlighting its ease of use, ARS Pharmaceuticals can drive sales and build brand loyalty. DTC campaigns can be particularly effective in reaching individuals who are hesitant to use traditional epinephrine auto-injectors. The investment in DTC marketing is expected to yield returns within 2-3 years.

What Threats Does SPRY Face?

• Competition from existing epinephrine auto-injectors.
• Regulatory setbacks or delays.
• Generic competition after patent expiration.
• Potential safety concerns or adverse events.

What Are SPRY's Competitive Advantages?

• Proprietary absorption technology for intranasal epinephrine delivery.
• Patent protection for ARS-1 (Neffy).
• First-mover advantage in the needle-free epinephrine market.
• Strong clinical data supporting the safety and efficacy of Neffy.

What Does SPRY Do?

ARS Pharmaceuticals, Inc., founded in 2015 and headquartered in San Diego, California, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for severe allergic reactions. The company's primary focus is on ARS-1, a novel intranasal epinephrine spray designed to provide a needle-free alternative to traditional epinephrine injections. ARS-1, branded as Neffy, utilizes a proprietary absorption technology to deliver epinephrine through the nasal passage, offering a potentially faster and more convenient method of administration for patients and caregivers. The development of Neffy addresses a significant unmet need in the treatment of anaphylaxis, a life-threatening allergic reaction. Traditional epinephrine auto-injectors, while effective, can be intimidating and difficult to use, particularly for children and individuals with needle phobias. Neffy aims to overcome these barriers by providing a user-friendly and readily accessible treatment option. ARS Pharmaceuticals is focused on obtaining regulatory approval for Neffy and establishing commercial partnerships to bring the product to market. The company's strategy involves extensive clinical trials to demonstrate the safety and efficacy of Neffy, as well as building a robust intellectual property portfolio to protect its innovative technology. With a team of experienced pharmaceutical professionals, ARS Pharmaceuticals is committed to improving the lives of individuals at risk of severe allergic reactions.

What Products and Services Does SPRY Offer?

• Develop a novel intranasal epinephrine spray called ARS-1 (Neffy).
• Offer a needle-free alternative to traditional epinephrine injections.
• Target patients and families at risk of severe allergic reactions.
• Utilize proprietary absorption technology for rapid epinephrine delivery.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from the FDA and other agencies.
• Establish commercial partnerships for market access.

How Does SPRY Make Money?

• Develop and patent novel drug delivery technologies.
• Conduct clinical trials to gain regulatory approval.
• Manufacture and market ARS-1 (Neffy).
• Generate revenue through product sales.
• Potentially license technology to other pharmaceutical companies.

What Industry Does SPRY Operate In?

ARS Pharmaceuticals operates within the biotechnology industry, specifically targeting the anaphylaxis treatment market. This market is characterized by a growing prevalence of allergies and a need for more convenient and user-friendly treatment options. The competitive landscape includes established pharmaceutical companies that manufacture epinephrine auto-injectors, as well as other companies developing alternative delivery methods. ARS Pharmaceuticals aims to differentiate itself through its needle-free intranasal spray, offering a potential advantage in terms of ease of use and patient acceptance. The overall market for allergy treatments is expected to continue to grow, driven by increasing awareness and diagnosis of allergic conditions.

Who Are SPRY's Key Customers?

• Individuals with severe allergies to food, medications, or insect bites.
• Parents and caregivers of children with allergies.
• Emergency medical personnel.
• Schools and other institutions that need to be prepared for allergic reactions.

Wall Street analysts project ARS Pharmaceuticals, Inc. revenue of about $132.3M for fiscal 2026, with EPS near $-1.76. The estimate reflects 3 contributing analysts.

ARS Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 164.3% above estimates on average.

ARS Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.55 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -68.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -22.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.94 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -25.1%, the inverse of the P/E and a quick read on earnings relative to price.

ARS Pharmaceuticals, Inc. (SPRY) Valuation Context

Valued at $547M, SPRY is classified as a small-cap stock. Relative to its peer group, SPRY's quantitative score of 9/100 is below the peer average of 64/100.

SPRY Revenue & Earnings Trend

In Q2 2026, SPRY generated $33.7M in top-line revenue, marking a sequential increase of 48.4%. The company recorded a net loss of $62.3M, with diluted EPS of $-0.63. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, SPRY averaged $-0.54 in diluted EPS.

Company Profile

ARS Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Donn Casale. SPRY has traded publicly since 2020.

SPRY Financials

SPRY Latest News

SPRY Analyst Consensus

SPRY MoonshotScore

Latest ARS Pharmaceuticals, Inc. Analysis

SPRY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources